| |
Current Financial Year 2019-20
| FY 19-20 |
Q1 |
H1 |
9M |
FY |
| Notice Ad |
 |
|
|
|
| Press Release |
|
|
|
|
| Fact Sheet |
|
|
|
|
| Transcript of the Call |
|
|
|
|
| Newspaper Advertisement |
|
|
|
|
| Results |
|
|
|
|
| Investor Presentation |
|
|
|
|
FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY20
Particulars |
Q1FY20 |
Q3FY19 |
Growth |
INCOME |
|
|
|
Small Molecules |
469 |
369 |
27% |
Biologics |
449 |
190 |
136% |
Branded Formulations |
212 |
156 |
36% |
Research Services |
467 |
388 |
20% |
Inter-segment |
-56 |
-45 |
26% |
Revenue from Operations# |
1,541 |
1,058 |
46% |
Other Income |
25 |
34 |
-24% |
TOTAL REVENUE |
1,566 |
1,092 |
43% |
EBITDA |
406 |
256 |
59% |
PBT |
289 |
150 |
93% |
Net Profit |
217 |
92 |
136% |
Exceptional item (net of tax) |
6 |
- |
|
Net Profit (adjusted for exceptional item) |
211 |
92 |
130% |
R&D Expenses in P&L |
77 |
53 |
45% |
|
Gross R&D Spends |
106 |
94 |
12% |
EBITDA Margin |
26% |
23% |
|
Core EBITDA Margin |
32% |
27% |
|
Net Profit Margin* |
14% |
8% |
|
#includes Licensing Income |
7 |
12 |
|
Year 2018-19 Financial Highlights
| In Rs. Crore |
| FY 18-19 |
Q1 |
H1 |
9M |
FY |
| Revenue |
988 |
1019 |
1092 |
1237 |
| EBITDA |
246 |
233 |
256 |
300 |
| Net Profit |
81 |
69 |
92 |
130 |
| R&D Expenses in P&L |
58 |
54 |
53 |
51 |
| Total R&D Spends |
96 |
93 |
94 |
98 |
| EBITDA Margins |
25% |
23% |
23% |
24% |
| Core EBITDA Margin |
29% |
27% |
27% |
26% |
| Net Profit Margins |
8% |
7% |
8% |
11% |
|
|
